84. サルコイドーシス Sarcoidosis Clinical trials / Disease details
臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-004794-31-NL (EUCTR) | 01/07/2022 | 10/05/2022 | A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory disease | A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis - Resolve-Lung | chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Namilumab Product Code: KIN-1902 INN or Proposed INN: NAMILUMAB | Kinevant Sciences GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | France;United States;Belgium;Turkey;Germany;Netherlands;United Kingdom | ||
| 2 | NCT05351554 (ClinicalTrials.gov) | June 30, 2022 | 4/4/2022 | A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis | A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis | Sarcoidosis, Cardiac | Drug: Namilumab;Drug: Placebo;Drug: Open label Namilumab | Kinevant Sciences GmbH | NULL | Terminated | 18 Years | N/A | All | 1 | Phase 2 | United States |
| 3 | NCT05314517 (ClinicalTrials.gov) | April 30, 2022 | 30/3/2022 | A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis | A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Namilumab;Drug: Placebo | Kinevant Sciences GmbH | NULL | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | United States;Belgium;France;Netherlands |